AnGes MG to Start Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.Tokyo, Japan, July 26, 2005 - (JCNN JCNN Japan Corporate News Network ) - AnGes MG announced on July 25 that the Pharmaceuticals and Medical Devices Agency (PMDA PMDA Plastics Machinery Distributors' Association (United Kingdom)
PMDA Plutonium Management and Disposition Agreement (US-Russia)
PMDA Pharmaceuticals and Medical Device Agency (Japan) ) has completed a preliminary 30-day examination of a clinical trial plan submitted by AnGes MG for NF-kappa B decoy oligodeoxynucleotide.
Accordingly, AnGes MG will soon start a phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained
phase I by signing trial contracts with medical institutions. Specifically, the proposed clinical trial will seek the feasibility of NF-kappa B decoy oligodeoxynucleotide in the field of atopic dermatitis.
In addition, AnGes MG has partnered with Alfresa Pharma and jointly conducted research on NF-kappa B decoy oligodeoxynucleotide, aiming to apply it to atopic dermatitis.
Source: JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.